Disease States: Schizophrenia

Schizophrenia

ISCTM 2024

Further Evaluation of the Procognitive Effect of KarXT in Acutely Symptomatic Schizophrenia: Consideration of Cognitive Subdomains and Methodological Factors

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Kaul, I et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2023 Dec 14:S0140-6736(23)02190-6. doi: 10.1016/S0140-6736(23)02190-6.

ACNP 2023

KarXT (Xanomeline–Trospium) for the Treatment of Agitation in Schizophrenia: PANSS–EC Results from Three Randomized, Double-Blind, Placebo-Controlled Trials

ACNP 2023

KarXT (Xanomeline–Trospium) Demonstrates Broad Efficacy in People With Schizophrenia Across a Wide Range of Demographic Subgroups: Pooled Results From the 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

ACNP 2023

The Muscarinic Agonist Xanomeline Demonstrates Antipsychotic Activity and Augments Clinical Antipsychotics in Rodent Behavioral Models of Psychosis

NEI 2023

Pooled Analysis of EPS-Like Symptoms in the EMERGENT Program of KarXT in Schizophrenia

NEI 2023

Safety and Tolerability of KarXT (Xanomeline–Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

NEI 2023

Efficacy of KarXT (Xanomeline–Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

ECNP 2023

Onset, Duration, and Severity of Adverse Events With KarXT (Xanomeline–Trospium) in the Randomised, Double-Blind,  Placebo-Controlled Phase 3 EMERGENT-3 Trial

ECNP 2023

Categorical Response Rates, Time Course of Response,and Symptom Domains of Response With KarXT(Xanomeline–Trospium) in the EMERGENT-3 Trial